Gilead Sciences’s most recent trend suggests a bearish bias. One trading opportunity on Gilead Sciences is a Bear Call Spread using a strike $74.00 short call and a strike $79.00 long call offers a potential 16.55% return on risk over the next 7 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $74.00 by expiration. The full premium credit of $0.71 would be kept by the premium seller. The risk of $4.29 would be incurred if the stock rose above the $79.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Gilead Sciences is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Gilead Sciences is bearish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Gilead Sciences
Edited Transcript of GILD earnings conference call or presentation 26-Oct-17 8:30pm GMT
Thu, 09 Nov 2017 07:41:02 +0000
Q3 2017 Gilead Sciences Inc Earnings Call
Cramer’s lightning round: Step aside, Exxon. Cimarex’s mo…
Thu, 09 Nov 2017 00:04:00 +0000
Jim Cramer zipped through his take on callers’ favorite stocks, including that of a smaller oil exploration company.
6 Reasons Gilead Didn’t Overpay for Kite
Wed, 08 Nov 2017 18:14:00 +0000
Shares of Gilead Sciences (GILD) have been on a steady downward slide since it hit a 52-week high in early September. Add to that, some investors remain unconvinced that Gilead didn’t overpay when it bought Kite Pharma for $12 billion. What do investors think of this deal and where are we?
How Gilead Sciences Has Maintained Its Dividend Trajectory
Wed, 08 Nov 2017 18:05:22 +0000
Gilead Sciences’ (GILD) revenue rose 31% in 2015 before falling 7% in 2016. Revenue from the United States, Europe, Japan, and other countries drove revenue growth in 2015. US and…
Today’s Research Reports on Trending Tickers: Exact Sciences and Gilead Sciences
Wed, 08 Nov 2017 13:00:00 +0000
NEW YORK, NY / ACCESSWIRE / November 8, 2017 / U.S. markets retreated from their record highs Tuesday on mixed earnings and falling bond yields. The Dow Jones Industrial Average gained 0.04 percent to …
Follow Us on Facebook